Publication number: 20090054426
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.
Type:
Application
Filed:
August 21, 2008
Publication date:
February 26, 2009
Applicant:
ABBOTT LABORATORIES
Inventors:
R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
Patent number: 6221865
Abstract: Compounds having the formula
or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from
(a)
(b) —C(O)NH—CH(R14)—C(O)OR15,
(d) —C(O)NH—CH(R14)—C(O)NHSO2R16,
(e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and
(g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl,
and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5—(d) —L4—L6—C(W)—N(R5)&md
Type:
Grant
Filed:
May 7, 1998
Date of Patent:
April 24, 2001
Assignee:
University of Pittsburgh
Inventors:
Said M. Sebti, Andrew D. Hamilton, Kenneth J. Barr, Stephen A. Fakhoury, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Bryan K. Sorensen, Gerard M. Sullivan, James T. Wasicak, Kenneth J. Henry, Le Wang
Patent number: 6204293
Abstract: Compounds having the formula
or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from
(b) —C(O)NH—CH(R14)—C(O)OR15,
(d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)&m
Type:
Grant
Filed:
May 7, 1998
Date of Patent:
March 20, 2001
Assignee:
University of Pittsburgh
Inventors:
Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Stephen A. Fakhoury, David A. Janowick, Douglas M. Kalvin, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Rolf E. Swenson, Bryan K. Sorensen, Gerard M. Sullivan, Andrew S. Tasker, James T. Wasicak, Lissa T. J. Nelson, Kenneth J. Henry, Le Wang, Gang Liu, Indrani W. Gunawardana
